Treatment of Granuloma Annulare with the 585 nm Pulsed Dye Laser

Sniezek, Patrick J.; Bloom, James R. De; Arpey, Christopher J.

doi:10.1111/j.1524-4725.2005.31224

Cited by 16 publications

(17 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunosuppression with methotrexate, cyclosporine, and TNF-a inhibitors can be considered in patients with severe disease that has been recalcitrant to other therapies. 28,[87][88][89][90][91][93][94][95][96][97][98][99][100][101][102][103][104][105][106][107][108][109][114][115][116][117][118][119][120][121][122][123][124]126,127,129,130,[132][133][134][140][141][142][144][145][146][147][148]150,…”

Section: Evaluation and Managementmentioning

confidence: 99%

Granuloma Annulare

Keimig

2015

Dermatologic Clinics

View full text Add to dashboard Cite

Granuloma annulare (GA) is a noninfectious granulomatous skin condition that can present with a variety of cutaneous morphologies. It is characterized by collagen degeneration, mucin deposition, and palisaded or interstitial histiocytes. Although the mechanism underlying development of GA is unknown, studies point to a cell-mediated hypersensitivity reaction to an as-yet undetermined antigen. Systemic associations with diabetes, thyroid disorders, lipid abnormalities, malignancy, and infection are described in atypical GA. Treatment is divided into localized skin-directed therapies and systemic immunomodulatory or immunosuppressive therapies. The selected treatment modality should be based on disease severity, comorbid conditions, consideration of potential side effects, and patient preference.

show abstract

Section: Evaluation and Managementmentioning

confidence: 99%

Granuloma Annulare

Keimig

2015

Dermatologic Clinics

View full text Add to dashboard Cite

show abstract

“…Two case reports and one retrospective study documented the use of PDL for the treatment of GA . All 14 patients were female, ranging in age from 4 to 66 years, with localized or generalized GA.…”

Section: Resultsmentioning

confidence: 99%

Laser treatment of granuloma annulare: a review

et al. 2015

View full text Add to dashboard Cite

Granuloma annulare (GA) is a benign asymptomatic dermatosis that typically manifests in papules arrayed in annular arrangements. Many methods of treatment have been used with variable degrees of success, but finding a consistent and long-term treatment has proven a challenge. This study was conducted in order to review and evaluate the latest published research on the use of lasers in the treatment of GA. A systematic search of the National Library of Medicine's PubMed database was performed to identify relevant articles. Seven reports met the inclusion criteria for the review. Evidence for the use of pulsed dye laser, fractional photothermolysis, and excimer laser in the treatment of GA was found. Findings are limited by a lack of well-designed clinical trials objectively evaluating the use of lasers in the treatment of GA. The literature review found a number of case reports and case series that report successful outcomes of the use of lasers in the treatment of GA. The promising results reported in the literature, coupled with the lack of a well-designed review on this topic, reflect the importance of this article to the dermatologic literature as it emphasizes the need for larger and better-designed studies on the use of lasers to treat GA.

show abstract

“…Granuloma annulare is a benign disease of unknown etiology with a lymphocyte-mediated hypersensitivity type IV mechanism where an immunologic cell-mediated process or a primary collagen and/or elastin destruction have often been suggested [8]. Lichen sclerosus is a chronic lymphocyte-mediated inflammatory skin disease, for which increasing evidence suggests an underlying autoimmune mechanism mainly in female genetically predisposed patients with HLA-DQ7 antigen; in fact antibodies against the basement membrane zone, chiefly Binding Protein (BP)180 and BP 230, have been found in 30% of sera of patients with LS, and a high proportion of patients (up to 80%) have specific antibodies targeting extracellular matrix protein-1 [9].…”

Section: Discussionmentioning

confidence: 99%